NBW Capital LLC Lowers Position in Eli Lilly and Company (NYSE:LLY)

NBW Capital LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 744 shares of the company’s stock after selling 17 shares during the period. NBW Capital LLC’s holdings in Eli Lilly and Company were worth $575,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of LLY. Emerald Mutual Fund Advisers Trust lifted its position in Eli Lilly and Company by 76.7% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 562 shares of the company’s stock valued at $498,000 after purchasing an additional 244 shares in the last quarter. Emerald Advisers LLC lifted its position in Eli Lilly and Company by 75.2% during the third quarter. Emerald Advisers LLC now owns 1,873 shares of the company’s stock valued at $1,659,000 after purchasing an additional 804 shares in the last quarter. BSW Wealth Partners lifted its position in Eli Lilly and Company by 4.3% during the third quarter. BSW Wealth Partners now owns 3,236 shares of the company’s stock valued at $2,867,000 after purchasing an additional 134 shares in the last quarter. Lansing Street Advisors lifted its position in Eli Lilly and Company by 3.3% during the third quarter. Lansing Street Advisors now owns 648 shares of the company’s stock valued at $575,000 after purchasing an additional 21 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its holdings in Eli Lilly and Company by 14.5% during the third quarter. Robeco Institutional Asset Management B.V. now owns 826,944 shares of the company’s stock valued at $732,623,000 after acquiring an additional 104,801 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on LLY shares. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a report on Thursday, January 16th. Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Truist Financial raised their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Citigroup decreased their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Finally, Wolfe Research started coverage on Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,000.28.

Eli Lilly and Company Trading Up 1.0 %

Shares of NYSE LLY opened at $930.22 on Tuesday. The business’s 50 day moving average is $817.56 and its two-hundred day moving average is $848.11. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53. The stock has a market capitalization of $882.01 billion, a P/E ratio of 79.44, a PEG ratio of 1.40 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has authorized a stock buyback program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.65%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is presently 51.24%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.